Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.
New bispecific antibodies offer treatment options for multiple myeloma patients who've exhausted standard therapies.
This concise clinical review summarizes FDA-approved and emerging bispecific antibodies for triple-refractory multiple myeloma, covering BCMA (teclistamab), GPRC5D (talquetamab), and FcRH5 (elranatamab) targeting agents with discussion of sequencing, toxicity management, and future combination approaches. Useful as a current state-of-the-field summary for the bispecific antibody landscape in RRMM.
What the study was
- Study design
- Narrative review
- Population
- Relapsed/refractory multiple myeloma patients, heavily pretreated
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cancer Investigation
Why it surfaced
Timely clinical review of FDA-approved bispecific antibodies in RRMM; useful for treatment-planning pipeline. Lower-impact journal limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.